BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 15473938)

  • 21. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
    Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
    J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
    Barker FG; Chang SM; Valk PE; Pounds TR; Prados MD
    Cancer; 1997 Jan; 79(1):115-26. PubMed ID: 8988735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
    Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography for radiation treatment planning.
    Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
    Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Postoperative
    Marner L; Nysom K; Sehested A; Borgwardt L; Mathiasen R; Henriksen OM; Lundemann M; Munck Af Rosenschöld P; Thomsen C; Bøgeskov L; Skjøth-Rasmussen J; Juhler M; Kruse A; Broholm H; Scheie D; Lauritsen T; Forman JL; Wehner PS; Højgaard L; Law I
    J Nucl Med; 2019 Aug; 60(8):1053-1058. PubMed ID: 30683767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-FET PET differentiation of ring-enhancing brain lesions.
    Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
    J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence.
    Gómez-Río M; Rodríguez-Fernández A; Ramos-Font C; López-Ramírez E; Llamas-Elvira JM
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):966-75. PubMed ID: 18172642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma.
    Dankbaar JW; Snijders TJ; Robe PA; Seute T; Eppinga W; Hendrikse J; De Keizer B
    J Neurooncol; 2015 Oct; 125(1):167-75. PubMed ID: 26384811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome.
    Valk PE; Budinger TF; Levin VA; Silver P; Gutin PH; Doyle WK
    J Neurosurg; 1988 Dec; 69(6):830-8. PubMed ID: 2848111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of dual-time point 18F-FDG PET/CT tumor-to-background ratio, intraoperative 5-aminolevulinic acid fluorescence scale, and Ki-67 index in high-grade glioma.
    Kim YI; Cho KG; Jang SJ
    Medicine (Baltimore); 2019 Feb; 98(8):e14397. PubMed ID: 30813140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI.
    Meerwein CM; Queiroz M; Kollias S; Hüllner M; Veit-Haibach P; Huber GF
    Swiss Med Wkly; 2015; 145():w14116. PubMed ID: 25701645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-grade gliomas in children: tumor volume response to radiation.
    Fisher BJ; Bauman GS; Leighton CE; Stitt L; Cairncross JG; Macdonald DR
    J Neurosurg; 1998 Jun; 88(6):969-74. PubMed ID: 9609290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
    Pfannenberg AC; Oechsle K; Bokemeyer C; Kollmannsberger C; Dohmen BM; Bares R; Hartmann JT; Vonthein R; Claussen CD
    World J Urol; 2004 Jun; 22(2):132-9. PubMed ID: 14735310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.